In Texas, on June 19, 2026, Castle Biosciences, Inc. (Nasdaq: CSTL), a health-focused company known for its innovative tests shaping patient care, revealed that the Compensation Committee of its Board of Directors approved restricted stock options on June 15, 2026.
